Recent Updates
Recently added Catalysts
GH Positive Sentiment

Kevin Sayer Joins Guardant Health Board of Directors

Key Takeaway: Guardant Health has appointed Kevin Sayer to its board of directors. Sayer, the former CEO of Dexcom, brings significant experience in digital health technology. His strategic leadership is anticipated to benefit Guardant Health as it continues to advance in precision oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kevin Sayer brings extensive experience in digital health technology.
  • His appointment is expected to enhance Guardant's strategic direction.
  • Guardant Health expresses excitement about his addition to the board.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology. “We are excited to welcome Kevin Sayer to Guardant’s board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Kevin has played a piv

Frequently Asked Questions

Who is Kevin Sayer?

Kevin Sayer is the former CEO of Dexcom and current Executive Chairman.

What is Guardant Health?

Guardant Health is a leading precision oncology company based in Palo Alto.

What role will Sayer play at Guardant Health?

Sayer will serve on the board of directors, providing strategic leadership.

Why is Sayer's appointment significant?

His experience in digital health technology is expected to benefit Guardant.

Last updated: Nov 3, 2026